/
ALGS
$5.43-$0.14 (-2.51%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$34.5M
6M shares
52-week range
$4.80 – $13.69
7% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
1.72%
Moderate
Price (6 mo)
Loading chart…
Change$-416.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4.4M | $13.9M | $15.5M | $3.9M | $2.2M |
| Cost of revenue | $1.3M | $2.3M | $3.3M | $0 | $0 | $0 | $0 | $930.0K |
| Gross profit | −$1.3M | −$2.3M | −$3.3M | $4.4M | $13.9M | $15.5M | $3.9M | $1.3M |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 57.5% |
| R&D | $10.5M | $44.0M | $79.9M | $104.2M | $85.1M | $73.0M | $70.3M | $69.5M |
| Operating income | −$13.7M | −$54.0M | −$97.8M | −$128.3M | −$97.6M | −$88.1M | −$89.2M | −$88.0M |
| EBITDA | −$12.4M | −$49.9M | −$105.1M | −$124.4M | −$92.3M | −$83.8M | −$128.3M | −$22.9M |
| Net income | −$13.9M | −$52.3M | −$108.5M | −$128.3M | −$96.0M | −$87.7M | −$131.2M | −$24.2M |
| Net margin | — | — | — | -2944.1% | -690.6% | -564.6% | -3326.0% | -1106.7% |
| EPS (diluted) | -0.66 | -2.38 | -3.18 | -3.22 | -2.25 | -3.52 | -20.94 | -2.45 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $20M | $-7.05 | $-7.95–$-6.29 | 5 |
| 2027 | $4M | $-4.49 | $-5.27–$-3.70 | 5 |
| 2028 | $52M | $-2.84 | $-7.36–$5.35 | 5 |
| 2029 | $178M | $-0.30 | $-0.48–$-0.09 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.06
Price
$5.43
Implied downside
-99%
Peer comparison
Aligos Therapeutics, Inc. Common Stock
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
www.aligos.com- Employees
- 82
- IPO / List date
- Oct 16, 2020
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds ALGS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 100,450 | $746.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-19 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded ALGS yet.
